United Therapeutics (FRA:UTH) ROCE %: 19.27% (As of Mar. 2026)


FRA:UTH United Therapeutics Corp FRA:UTH
82 GF Score
Price €473.30
GF Value €337.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics ROCE %?

United Therapeutics FRA:UTH -2.65% 82 ROCE % is 19.27% as of Mar. 2026. GuruFocus rates FRA:UTH with a GF Score™ of 82/100 and a GF Value™ of €337.25 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. United Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.27%.

United Therapeutics  (FRA:UTH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

United Therapeutics ROCE % Related Terms

United Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for United Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics ROCE % Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.84 19.16 21.81 24.84 23.54

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.79 22.36 24.64 25.35 19.27
FRA:UTH
82GF Score
United Therapeutics Corp FRA:UTH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics ROCE % Calculation

United Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1480.324/( ( (7032.62 - 704.886) + (6729.52 - 478.752) )/ 2 )
=1480.324/( (6327.734+6250.768)/ 2 )
=1480.324/6289.251
=23.54 %

United Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=1111.696/( ( (6729.52 - 478.752) + (5807.783 - 518.221) )/ 2 )
=1111.696/( ( 6250.768 + 5289.562 )/ 2 )
=1111.696/5770.165
=19.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.27% mean?
United Therapeutics (FRA:UTH) has a ROCE % of 19.27% as of Mar. 2026.
Is United Therapeutics' ROCE % too high?
United Therapeutics' current ROCE % is 19.27%. The Drug Manufacturers industry median ROCE % is 7.00. United Therapeutics' value of 19.27% is 175.5% above this industry median. Overall, United Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' ROCE % compare to VTRS and NBIX?
United Therapeutics' ROCE % of 19.27% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. United Therapeutics' value of 19.27% is 175.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current ROCE % of 19.27% is 175.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current ROCE % is 19.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €337.25, compared to a current price of €473.30 — trading 40.3% above its estimated fair value. The current ROCE % is 19.27% and 175.5% above the Drug Manufacturers industry median of 7.00. United Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current ROCE % is 19.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (FRA:UTH) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of €473.30 is trading 40.3% above its estimated GF Value™ of €337.25. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:UTH:

  • ROCE %: 19.27%
  • GF Value™: €337.25 vs. price of €473.30 (40.3% above fair value)
  • GF Score™: 82/100 with 7 warning signs
  • Industry Position: 175.5% above the Drug Manufacturers median

No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTHR:USAU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
82GF Score

Get the complete analysis for FRA:UTH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€473.30
Price
€337.25
GF Value